admin – Page 2667 – Get News Story

Retinal Vein Occlusion Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmace

“Retinal Vein Occlusion Pipeline”

DelveInsight’s, “Retinal Vein Occlusion – Pipeline Insight, 2025,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Retinal Vein Occlusion pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight reports that over 15 key companies are actively engaged in developing more than 15 therapies for the treatment of Retinal Vein Occlusion.

Retinal Vein Occlusion Overview:

Retinal vein occlusion (RVO) is the second most common retinal vascular disorder and a leading cause of vision loss in older adults. It is classified into branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). CRVO occurs when the main retinal vein becomes obstructed behind the lamina cribrosa of the optic nerve, most often due to thrombosis. It is further divided into non-ischemic (perfused) and ischemic (non-perfused) types, with the non-ischemic form accounting for about 70% of cases.

Age is the strongest risk factor for CRVO, with 90% of cases occurring in people over 50. Other major risks include systemic hypertension, open-angle glaucoma, diabetes mellitus, and hyperlipidemia. Additional factors include smoking, optic disc drusen or edema, and various hypercoagulable states such as polycythemia, multiple myeloma, cryoglobulinemia, Waldenström macroglobulinemia, antiphospholipid syndrome, factor V Leiden mutation, activated protein C resistance, hyperhomocysteinemia, and deficiencies in Protein C, Protein S, or antithrombin III. Conditions such as syphilis, sarcoidosis, sickle cell disease, HIV, vasculitis, and certain medications like oral contraceptives or diuretics may also contribute. In rare cases, migraines or orbital diseases can play a role in the onset of CRVO.

Request for a detailed insights report on Retinal Vein Occlusion pipeline insights

“Retinal Vein Occlusion Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Retinal Vein Occlusion Therapeutics Market.

Key Takeaways from the Retinal Vein Occlusion Pipeline Report

DelveInsight’s Retinal Vein Occlusion (RVO) pipeline report showcases an active landscape with more than 15 companies working on over 15 potential therapies.
Key players include Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys, and others, all striving to improve RVO treatment options.
Prominent candidates in development include KSI-301, 601, and IBE-814, among others.
In December 2025, Regeneron and Bayer announced that Eylea HD (aflibercept 8 mg) achieved its primary endpoint in a Phase III trial for macular edema following RVO. Patients treated every eight weeks with Eylea HD achieved non-inferior visual gains compared to the original Eylea administered every four weeks, indicating the potential for extended dosing intervals and reduced treatment burden. Regeneron intends to submit these findings to the FDA in early 2025 to expand Eylea HD’s indications to include RVO.
In October 2023, the U.S. FDA approved Genentech’s Vabysmo (faricimab-svoa) for macular edema following RVO, based on positive Phase III BALATON and COMINO trial results. Monthly Vabysmo injections delivered early and sustained vision improvements in both branch and central RVO, achieving non-inferior visual acuity gains at 24 weeks compared to aflibercept, along with rapid and significant retinal fluid reduction. The safety profile aligned with prior studies, with conjunctival hemorrhage (3%) as the most common adverse event.

Retinal Vein Occlusion Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the key companies that are developing therapies in the Retinal Vein Occlusion Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinal Vein Occlusion treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Retinal Vein Occlusion market.

Download our free sample page report on Retinal Vein Occlusion pipeline insights

Retinal Vein Occlusion Emerging Drugs

KSI-301: Kodiak sciences
601: Sunshine Guojian Pharmaceutical
IBE-814: Ripple Therapeutics

Retinal Vein Occlusion Companies

Over 15 leading companies are actively engaged in developing treatments for Retinal Vein Occlusion, with Kodiak Sciences advancing a drug candidate currently in Phase III clinical trials.

DelveInsight’s report covers around 15+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Retinal Vein Occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Retinal Vein Occlusion Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Retinal Vein Occlusion Therapies and Key Companies: Retinal Vein Occlusion Clinical Trials and advancements

Retinal Vein Occlusion Pipeline Therapeutic Assessment

• Retinal Vein Occlusion Assessment by Product Type

• Retinal Vein Occlusion By Stage

• Retinal Vein Occlusion Assessment by Route of Administration

• Retinal Vein Occlusion Assessment by Molecule Type

Download Retinal Vein Occlusion Sample report to know in detail about the Retinal Vein Occlusion treatment market @ Retinal Vein Occlusion Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Retinal Vein Occlusion Current Treatment Patterns

4. Retinal Vein Occlusion – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Retinal Vein Occlusion Late-Stage Products (Phase-III)

7. Retinal Vein Occlusion Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Retinal Vein Occlusion Discontinued Products

13. Retinal Vein Occlusion Product Profiles

14. Retinal Vein Occlusion Key Companies

15. Retinal Vein Occlusion Key Products

16. Dormant and Discontinued Products

17. Retinal Vein Occlusion Unmet Needs

18. Retinal Vein Occlusion Future Perspectives

19. Retinal Vein Occlusion Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Retinal Vein Occlusion Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Retinal Vein Occlusion Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmace

Multiple System Atrophy Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Theravance Biopharma, Alterity Therapeutics, AskBio, Kainos Medicines, CORESTEM,

“Multiple System Atrophy Pipeline”

DelveInsight’s, “Multiple System Atrophy- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Multiple System Atrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight reports that over 20 key companies are actively developing more than 22 therapies for the treatment of Multiple System Atrophy.

Multiple System Atrophy Overview:

Multiple system atrophy (MSA) is a rare, progressive neurodegenerative disorder affecting an estimated 15,000 to 50,000 people in the United States across all racial groups. Its exact cause remains unknown, with most cases occurring sporadically without a clear pattern. MSA impacts both the central nervous system, which controls movement, and the autonomic nervous system, which manages involuntary functions such as blood pressure regulation and digestion. Over time, the disease causes degeneration of nerve cells in the brain and spinal cord, producing a range of symptoms. Classified as an atypical parkinsonian disorder, MSA often begins with signs resembling Parkinson’s disease—slowed movement, tremors, stiffness, poor coordination, dizziness or fainting, bladder problems, and a quivering voice.

MSA is divided into two main subtypes. MSA-P (Parkinsonian type) presents primarily with Parkinson’s-like symptoms, including tremors, rigidity, slow movement, balance issues, and autonomic dysfunction affecting urinary and digestive systems. MSA-C (Cerebellar type) is marked by coordination and balance problems (ataxia), speech and swallowing difficulties, voice tremors, and abnormal eye movements. Diagnosing MSA is challenging, particularly in early stages, due to its symptom overlap with Parkinson’s disease. Physicians rely on medical and family history, neurological examinations, and specialized tests, such as autonomic function assessments, bladder evaluations, MRI scans for brain changes, PET scans for metabolic activity, and DaT scans to measure dopamine distribution and activity in the brain.

Request for a detailed insights report on Multiple System Atrophy pipeline insights

“Multiple System Atrophy Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Multiple System Atrophy Therapeutics Market.

Key Takeaways from the Multiple System Atrophy Pipeline Report

DelveInsight’s Multiple System Atrophy (MSA) pipeline report highlights a strong development landscape with over 20 active companies advancing more than 22 potential therapies.
Key players include Theravance Biopharma, Alterity Therapeutics, AskBio, Kainos Medicines, CORESTEM, ProMIS Neuroscience, H. Lundbeck A/S, and others, all working to bring new treatment options to market. Prominent candidates in development include Ampreloxetine, ATH434, AB-1005, and more.
In February 2025, the U.S. FDA granted Fast Track Designation to Lundbeck’s investigational drug amlenetug for MSA, following positive Phase II AMULET trial results presented in March 2024. Lundbeck has since launched the Phase III MASCOT trial to further evaluate its efficacy and safety.
In January 2025, Alterity Therapeutics reported favorable topline Phase II data for ATH434, showing it was well-tolerated, reduced iron accumulation in affected brain regions, and slowed disease progression by 48% over 52 weeks at the 50 mg dose compared to placebo. In October 2023, Inhibikase Therapeutics received Orphan Drug Designation for risvodetinib (IkT-148009) for MSA treatment, backed by preclinical evidence suggesting therapeutic activity in MSA models. This designation provides development incentives and reflects the urgent need for effective therapies in this rare condition.

Multiple System Atrophy Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the key companies that are developing therapies in the Multiple System Atrophy Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple System Atrophy treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Multiple System Atrophy market.

Download our free sample page report on Multiple System Atrophy pipeline insights

Multiple System Atrophy Emerging Drugs

Ampreloxetine: Theravance Biopharma
ATH434: Alterity Therapeutics
AB-1005: AskBio

Multiple System Atrophy Companies

Over 20 major companies are actively developing therapies for Multiple System Atrophy, with Theravance Biopharma advancing a drug candidate to the most advanced stage—Phase III clinical trials.

DelveInsight’s report covers around 22+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Multiple System Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Multiple System Atrophy Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Multiple System Atrophy Therapies and Key Companies: Multiple System Atrophy Clinical Trials and advancements

Multiple System Atrophy Pipeline Therapeutic Assessment

• Multiple System Atrophy Assessment by Product Type

• Multiple System Atrophy By Stage

• Multiple System Atrophy Assessment by Route of Administration

• Multiple System Atrophy Assessment by Molecule Type

Download Multiple System Atrophy Sample report to know in detail about the Multiple System Atrophy treatment market @ Multiple System Atrophy Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Multiple System Atrophy Current Treatment Patterns

4. Multiple System Atrophy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Multiple System Atrophy Late-Stage Products (Phase-III)

7. Multiple System Atrophy Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Multiple System Atrophy Discontinued Products

13. Multiple System Atrophy Product Profiles

14. Multiple System Atrophy Key Companies

15. Multiple System Atrophy Key Products

16. Dormant and Discontinued Products

17. Multiple System Atrophy Unmet Needs

18. Multiple System Atrophy Future Perspectives

19. Multiple System Atrophy Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Multiple System Atrophy Pipeline Reports Offerings

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple System Atrophy Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Theravance Biopharma, Alterity Therapeutics, AskBio, Kainos Medicines, CORESTEM,

Water warts Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, Pipeline Analysis | Novan, Veloce Biopharma, Verrica Pharmaceuticals, Santalis Healthcare

“Water warts Pipeline Analysis”

The report covers the pipeline drug profiles, including clinical and nonclinical stage products.

DelveInsight’s analysis indicates that the Water Warts pipeline features over ten key companies actively working on the development of more than ten treatment therapies for the condition.

Water warts Overview:

Water warts, medically referred to as molluscum contagiosum, are a common viral skin infection caused by the molluscum contagiosum virus (MCV), a member of the poxvirus family. They typically present as small, smooth, firm, dome-shaped papules with a central dimple (umbilication) and may appear flesh-colored, white, or pink.

The condition spreads through direct skin-to-skin contact or indirectly via contaminated objects such as towels or gym equipment. It is more frequently seen in children, individuals with weakened immune systems, and those living in warm, humid environments. In children, lesions often appear on the face, trunk, arms, and legs, while in adults, they are commonly found in the genital area, abdomen, and inner thighs. Although usually painless, water warts can sometimes cause itching, redness, or mild inflammation.

Diagnosis is generally clinical, based on the distinctive appearance of the lesions, and rarely requires laboratory testing. While molluscum contagiosum is self-limiting and may resolve within 6–12 months in healthy individuals, treatment is often pursued to prevent spread and scarring. Management options include topical agents such as retinoids, salicylic acid, potassium hydroxide, and imiquimod, as well as procedural interventions like cryotherapy, curettage, or laser therapy. The prognosis is favorable in most cases, though the condition can be more persistent in immunocompromised patients.

Request for a detailed insights report on Water warts pipeline insights

“Water warts Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Water warts Therapeutics Market.

Key Takeaways from the Water warts Pipeline Report

DelveInsight’s Water Warts pipeline report highlights a dynamic landscape, with over 10 active companies engaged in developing more than 10 treatment candidates for the condition.
Leading players such as Novan, Veloce Biopharma, Verrica Pharmaceuticals, Santalis Healthcare, and others are advancing innovative therapies aimed at enhancing the current treatment options.
Notable pipeline candidates include SB 206 (Berdazimer Sodium) and VBP-245 (Povidone Iodine Topical), among others, which are progressing through various stages of clinical development.
A significant milestone was reached on January 5, 2024, when the FDA approved Zelsuvmi for treating water warts in both adults and children aged 1 year and older. Zelsuvmi is the first topical prescription treatment that can be applied by patients, parents, or caregivers at home, without requiring a clinical setting. Its approval was supported by results from the Phase 3 B-SIMPLE4 trial, where 32.4% of patients using berdazimer gel achieved complete clearance of lesions within 12 weeks, compared to 19.7% in the placebo group. The most frequently reported side effects were mild to moderate application site pain and erythema.

Water warts Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the key companies that are developing therapies in the Water warts Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Water warts treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Water warts market.

Download our free sample page report on Water warts pipeline insights

Water warts Emerging Drugs

SB 206 (Berdazimer Sodium): Novan Inc
VBP-245 (Povidone Iodine Topical): Veloce Biopharma

Water warts Companies

Over 10 key companies are actively developing therapies for Water Warts, with Novan Inc. leading the field with a drug candidate currently in the most advanced stage—Phase III clinical trials.

DelveInsight’s report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Water warts pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Water warts Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Water warts Therapies and Key Companies: Water warts Clinical Trials and advancements

Water warts Pipeline Therapeutic Assessment

• Water warts Assessment by Product Type

• Water warts By Stage

• Water warts Assessment by Route of Administration

• Water warts Assessment by Molecule Type

Download Water warts Sample report to know in detail about the Water warts treatment market @ Water warts Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Water warts Current Treatment Patterns

4. Water warts – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Water warts Late-Stage Products (Phase-III)

7. Water warts Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Water warts Discontinued Products

13. Water warts Product Profiles

14. Water warts Key Companies

15. Water warts Key Products

16. Dormant and Discontinued Products

17. Water warts Unmet Needs

18. Water warts Future Perspectives

19. Water warts Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Water warts Pipeline Reports Offerings

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Water warts Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, Pipeline Analysis | Novan, Veloce Biopharma, Verrica Pharmaceuticals, Santalis Healthcare

AAV Vectors in Gene Therapy Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Belief BioMed, Gensight Biologics, Johnson & Johnson Innovative Medicine

“AAV Vectors in Gene Therapy Pipeline”

DelveInsight’s, “Adeno-Associated Virus (AAV) Vectors in Gene Therapy – Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 250+ pipeline drugs in AAV Vectors in Gene Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight reports that over 180 key companies are actively developing more than 200 therapies utilizing AAV vectors in gene therapy.

AAV Vectors in Gene Therapy Overview:

Adeno-associated virus (AAV) vectors are highly effective gene therapy delivery tools, valued for their precision in delivering therapeutic genes to target cells while eliciting minimal immune response. Naturally occurring in humans and non-pathogenic, AAVs are considered safe since they are not linked to any known diseases. Their ability to enable long-term or sustained gene expression makes them ideal for in vivo applications, as they can integrate into cells and maintain function over extended periods.

Various AAV serotypes have distinct tissue-targeting abilities, allowing therapies to be tailored for specific diseases. For example, AAV9 can cross the blood–brain barrier, making it suitable for central nervous system (CNS) disorders, while AAV2 is particularly effective for ocular treatments. This versatility enables AAV vectors to treat a range of genetic disorders, including hemophilia, spinal muscular atrophy (SMA), and inherited retinal diseases. Notably, AAV-based therapies such as Luxturna and Zolgensma have already gained regulatory approval for rare genetic conditions, representing major milestones in gene therapy advancement.

Request for a detailed insights report on AAV Vectors in Gene Therapy pipeline insights @ https://www.delveinsight.com/report-store/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

“AAV Vectors in Gene Therapy Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the AAV Vectors in Gene Therapy Therapeutics Market.

Key Takeaways from the AAV Vectors in Gene Therapy Pipeline Report

DelveInsight’s AAV Vectors in Gene Therapy pipeline report outlines a dynamic field with over 25 active companies developing more than 30 therapies.
Leading players include Belief BioMed, Gensight Biologics, Johnson & Johnson Innovative Medicine, MeiraGTx, Passage Bio, InnoVec Biotherapeutics, Ultragenyx Pharmaceutical, Biogen, REGENXBIO, Beacon Therapeutics, Genethon, 4D Molecular Therapeutics, Adverum Biotechnologies, Rocket Pharmaceuticals, Aspa Therapeutics, Sarepta Therapeutics, Ray Therapeutics, Genascence Corporation, Exegenesis Bio, DiNAQOR, Tenaya Therapeutics, Jaguar Gene Therapy, Neurophth, and others, all aiming to advance the treatment landscape.
Notable candidates in development include BBM-H901, GS010, AAV-CNGA3, PBGM01, and IVB102.
In June 2023, the FDA approved Roctavian by BioMarin Pharmaceutical for adults with severe hemophilia A. This AAV-based therapy delivers a functional gene for clotting Factor VIII, significantly reducing annual bleeding rates in trials. That same month, the FDA granted accelerated approval to Elevidys by Sarepta Therapeutics for children aged 4–5 with Duchenne muscular dystrophy (DMD), designed to restore muscle function by introducing a shortened dystrophin gene.
However, the field has also seen setbacks. In December 2025, Pfizer ended its partnership with Sangamo Therapeutics on the hemophilia A therapy giroctocogene fitelparvovec, despite positive Phase 3 results, citing clinical feedback and limited market demand. In March 2025, safety concerns arose when a patient treated with Elevidys developed acute liver failure and died, with concurrent cytomegalovirus infection potentially contributing. This incident heightened scrutiny of AAV-based therapies’ liver-related risks and affected Sarepta’s market position.

AAV Vectors in Gene Therapy Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the key companies that are developing therapies in the AAV Vectors in Gene Therapy Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for AAV Vectors in Gene Therapy treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the AAV Vectors in Gene Therapy market.

Download our free sample page report on AAV Vectors in Gene Therapy pipeline insights

AAV Vectors in Gene Therapy Emerging Drugs

BBM-H901: Belief BioMed
GS010: Gensight Biologics
AAV-CNGA3: Johnson & Johnson Innovative Medicine/ MeiraGTx
PBGM01: Passage Bio
IVB102: InnoVec Biotherapeutics

AAV Vectors in Gene Therapy Companies

Over 180 major companies are working on gene therapy treatments using Adeno-Associated Virus (AAV) vectors, with Belief BioMed advancing drug candidates to the most progressed stage—the registration phase.

DelveInsight’s report covers around 30+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

AAV Vectors in Gene Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

AAV Vectors in Gene Therapy Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging AAV Vectors in Gene Therapy Therapies and Key Companies: AAV Vectors in Gene Therapy Clinical Trials and advancements

AAV Vectors in Gene Therapy Pipeline Therapeutic Assessment

• AAV Vectors in Gene Therapy Assessment by Product Type

• AAV Vectors in Gene Therapy By Stage

• AAV Vectors in Gene Therapy Assessment by Route of Administration

• AAV Vectors in Gene Therapy Assessment by Molecule Type

Download AAV Vectors in Gene Therapy Sample report to know in detail about the AAV Vectors in Gene Therapy treatment market @ AAV Vectors in Gene Therapy Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. AAV Vectors in Gene Therapy Current Treatment Patterns

4. AAV Vectors in Gene Therapy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. AAV Vectors in Gene Therapy Late-Stage Products (Phase-III)

7. AAV Vectors in Gene Therapy Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. AAV Vectors in Gene Therapy Discontinued Products

13. AAV Vectors in Gene Therapy Product Profiles

14. AAV Vectors in Gene Therapy Key Companies

15. AAV Vectors in Gene Therapy Key Products

16. Dormant and Discontinued Products

17. AAV Vectors in Gene Therapy Unmet Needs

18. AAV Vectors in Gene Therapy Future Perspectives

19. AAV Vectors in Gene Therapy Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the AAV Vectors in Gene Therapy Pipeline Reports Offerings

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AAV Vectors in Gene Therapy Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Belief BioMed, Gensight Biologics, Johnson & Johnson Innovative Medicine

Alzheimer’s disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therape

“Alzheimer’s disease Pipeline Insights”

DelveInsight’s, “Alzheimer’s disease Pipeline Insight, 2025” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Alzheimer’s disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight reports that over 110 key companies are actively engaged in developing more than 120 treatment therapies for Alzheimer’s disease.

Alzheimer’s disease Overview:

Alzheimer’s disease (AD) is the leading cause of dementia, marked by progressive brain cell loss, cognitive decline, and loss of independence. It has complex causes, with aging, genetics, trauma, vascular issues, infections, and environmental factors among the main risks. Two major theories explain its development: the cholinergic and amyloid hypotheses.

Neuropathological changes include positive lesions (amyloid plaques, neurofibrillary tangles, and abnormal deposits) and negative lesions (neuronal and synaptic loss, brain atrophy). Additional factors like neuroinflammation, oxidative stress, and cholinergic neuron damage further drive degeneration.

Symptoms progress through three stages—preclinical, mild, and dementia-stage. Early signs often involve short-term memory loss, followed by impairments in judgment, problem-solving, organization, and abstract thinking, along with language and visuospatial difficulties. Later stages bring neuropsychiatric issues (apathy, agitation, psychosis), motor and sensory problems, sleep disturbances, and Parkinsonian-like features. In advanced disease, patients become fully dependent, with incontinence and loss of basic functions.

Request for a detailed insights report on Alzheimer’s disease pipeline insights @ https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

“Alzheimer’s disease Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Alzheimer’s disease Therapeutics Market.

Key Takeaways from the Alzheimer’s disease Pipeline Report

DelveInsight’s Alzheimer’s disease pipeline report highlights a dynamic landscape with over 110 active companies developing more than 120 potential therapies.
Leading players include AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Cassava Sciences, BioVie Inc., Novo Nordisk, Alector Inc., Longeveron Inc., TrueBinding, VT BIO, Luye Pharma Group, Lexeo Therapeutics, Merck Sharp & Dohme, Regeneration Biomedical, Alnylam Pharmaceuticals, Sinotau Pharmaceutical Group, Eisai Inc., Shanghai Hengrui Pharmaceutical, and others, all working to advance novel treatments.
Key candidates in development include AR1001, NE3107, LY3372689, CT1812, ABBV-916, and ALX-001, among others.
Notably, in January 2023, the U.S. FDA granted accelerated approval to Leqembi, an amyloid beta-directed antibody that reduces amyloid plaques in the brain. This decision was based on early evidence of clinical benefit. By July 2023, Leqembi received full FDA approval following Phase 3 trial results confirming its effectiveness in slowing cognitive decline in patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease.

Alzheimer’s disease Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the key companies that are developing therapies in the Alzheimer’s disease Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer’s disease treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Alzheimer’s disease market.

Download our free sample page report on Alzheimer’s disease pipeline insights

Alzheimer’s disease Emerging Drugs

AR1001: AriBio Co., Ltd.
NE3107: BioVie
LY3372689: Eli Lilly & Co.
CT1812: Cognition Therapeutics
ABBV-916: AbbVie Inc.
ALX-001: Allyx Therapeutics, Inc.

Alzheimer’s disease Companies

Approximately 110 companies are engaged in developing therapies for Alzheimer’s disease, with AriBio Co., Ltd. and BioVie among those advancing drug candidates to the most progressed stage—Phase III clinical trials.

DelveInsight’s report covers around 120+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Alzheimer’s disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Alzheimer’s disease Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Alzheimer’s disease Therapies and Key Companies: Alzheimer’s disease Clinical Trials and advancements

Alzheimer’s disease Pipeline Therapeutic Assessment

• Alzheimer’s disease Assessment by Product Type

• Alzheimer’s disease By Stage

• Alzheimer’s disease Assessment by Route of Administration

• Alzheimer’s disease Assessment by Molecule Type

Download Alzheimer’s disease Sample report to know in detail about the Alzheimer’s disease treatment market @ Alzheimer’s disease Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Alzheimer’s disease Current Treatment Patterns

4. Alzheimer’s disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Alzheimer’s disease Late-Stage Products (Phase-III)

7. Alzheimer’s disease Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Alzheimer’s disease Discontinued Products

13. Alzheimer’s disease Product Profiles

14. Alzheimer’s disease Key Companies

15. Alzheimer’s disease Key Products

16. Dormant and Discontinued Products

17. Alzheimer’s disease Unmet Needs

18. Alzheimer’s disease Future Perspectives

19. Alzheimer’s disease Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Alzheimer’s disease Pipeline Reports Offerings

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alzheimer’s disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therape

Tendonitis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Seikagaku Corporation, MetrioPharm, MiMedx, Zhejia

“Tendonitis Pipeline Analysis”

DelveInsight’s, “Tendonitis Pipeline Insight 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Tendonitis pipeline landscape. It covers the Tendonitis pipeline drug profiles, including Tendonitis clinical trials and nonclinical stage products. It also covers the Tendonitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight reports that more than four key companies are actively engaged in developing over four treatment therapies for Tendonitis.

Tendonitis Overview:

Tendonitis, also called tendinopathy, is the inflammation of a tendon — the tough connective tissue that links muscles to bones. It often develops due to injury, trauma, or repetitive joint movements. Based on the affected area, it may be referred to by specific names such as Achilles tendonitis or tennis elbow.

The condition commonly impacts the elbows, heels, shoulders, and wrists. Standard treatment includes rest, pain-relief medications, and anti-inflammatory drugs, while physical therapy helps strengthen muscles and support recovery. In more severe cases, surgical intervention may be necessary to repair the damaged tendon.

Request for a detailed insights report on Tendonitis pipeline insights @ https://www.delveinsight.com/report-store/tendonitis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

“Tendonitis Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Tendonitis Therapeutics Market.

Key Takeaways from the Tendonitis Pipeline Report

DelveInsight’s Tendonitis pipeline report highlights a strong development landscape, with over four active companies working on more than four therapies for treating Tendonitis.
Key players in this space include Seikagaku Corporation, MetrioPharm, MiMedx, Zhejiang Xingyue Biotechnology Co., Ltd., R3 Stem Cell, Dobecure, Causeway Therapeutics, and others, all aiming to introduce innovative drugs to enhance treatment options.
Notable pipeline candidates currently in various stages of development include SI-613, MP1032, and others.
In addition, device-based innovations are emerging — for instance, TendoNova’s Ocelot, a handheld tool for mechanically fragmenting and debriding targeted tendon tissues, received FDA 510(k) clearance in May 2022 for commercial use in conditions such as tennis elbow and plantar fasciitis. Similarly, in May 2022, CoNextions Inc. secured FDA 510(k) clearance for a device designed to improve healing and functional outcomes in tendon repair surgeries.

Tendonitis Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the key companies that are developing therapies in the Tendonitis Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Tendonitis treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Tendonitis market.

Download our free sample page report on Tendonitis pipeline insights

Tendonitis Emerging Drugs

SI-613: Seikagaku Corporation
MP1032: MetrioPharm

Tendonitis Companies

Around four major companies are actively developing therapies for tendonitis, with Seikagaku Corporation having one of the most advanced drug candidates currently in Phase II clinical trials.

DelveInsight’s report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Tendonitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Tendonitis Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Tendonitis Therapies and Key Companies: Tendonitis Clinical Trials and advancements

Tendonitis Pipeline Therapeutic Assessment

• Tendonitis Assessment by Product Type

• Tendonitis By Stage

• Tendonitis Assessment by Route of Administration

• Tendonitis Assessment by Molecule Type

Download Tendonitis Sample report to know in detail about the Tendonitis treatment market @ Tendonitis Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Tendonitis Current Treatment Patterns

4. Tendonitis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Tendonitis Late-Stage Products (Phase-III)

7. Tendonitis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Tendonitis Discontinued Products

13. Tendonitis Product Profiles

14. Tendonitis Key Companies

15. Tendonitis Key Products

16. Dormant and Discontinued Products

17. Tendonitis Unmet Needs

18. Tendonitis Future Perspectives

19. Tendonitis Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Tendonitis Pipeline Reports Offerings

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Tendonitis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Seikagaku Corporation, MetrioPharm, MiMedx, Zhejia

Acoustic Neuroma Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

“Acoustic Neuroma Market”

Acoustic Neuroma companies are Akouos, Amgen, Roche, Natus Medical Incorporated, Elekta, Pfizer Inc., Roche AG, CIVCO MEDICAL SOLUTIONS, Novartis AG, MAICO Diagnostics GmbH, Siemens Healthcare GmbH, Interacoustics A/S, Natus Medical Incorporated, and others.

(Albany, USA) DelveInsight’s report, “Acoustic Neuroma Market Insights, Epidemiology, and Market Forecast–2034”, offers a comprehensive analysis of Acoustic Neuroma, including historical and projected epidemiology, along with market trends across the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The report details current treatment practices, emerging therapies, market share by individual treatments, and the Acoustic Neuroma market size from 2020 to 2034, segmented across the seven major markets. It further outlines the existing treatment algorithms, key market drivers and barriers, as well as unmet medical needs—identifying the best growth opportunities and evaluating the market’s overall potential.

Request for a Free Sample Report @ Acoustic Neuroma Market Forecast

Some facts of the Acoustic Neuroma Market Report are:

According to DelveInsight, Acoustic Neuroma market size is expected to grow at a decent CAGR by 2034.
Leading Acoustic Neuroma companies working in the market are Akouos, Amgen, Roche, Natus Medical Incorporated, Elekta, Pfizer Inc., Roche AG, CIVCO MEDICAL SOLUTIONS, Novartis AG, MAICO Diagnostics GmbH, Siemens Healthcare GmbH, Interacoustics A/S, Natus Medical Incorporated, and others.
Key Acoustic Neuroma Therapies expected to launch in the market are AK-antiVEGF, and many others.
In August 2025, Akouos, Inc announced results of a Phase 1/2 Trial of AAVAnc80-antiVEGF Gene Therapy in Individuals With Unilateral Vestibular Schwannoma
In April 2025, Reveal Pharmaceuticals Inc announced results of a Multi-Center, Phase 2, Open Label, Ascending Dose Study to Evaluate the Safety and Efficacy of RVP-001 and to Identify an Appropriate Dose to Detect CNS Lesions in Adult Patients
According to our finding, the overall incidence of vestibular schwannoma is approximately 3 to 5 per 100,000 person-years. The incidence rises with advancing age. For patients over 70 years of age, the incidence may be as high as 21 per 100,000 person-years.
As per Greene J et al. (2024), Schwannomas account for approximately 8% of all clinically manifested intracranial tumors. However, genetic factors contribute to developing bilateral acoustic neuromas, constituting less than 5% of all schwannomas.

Acoustic Neuroma Overview

Acoustic neuroma, also known as vestibular schwannoma, is a rare, typically benign tumor that develops from the Schwann cells covering the vestibulocochlear nerve (cranial nerve VIII), which is responsible for hearing and balance. These tumors grow slowly and are usually located between the inner ear and the brain. The condition often presents with unilateral or asymmetric hearing loss, tinnitus (ringing in the ear), dizziness, and balance disturbances. As the tumor enlarges, it can compress adjacent cranial nerves, including the trigeminal nerve, leading to facial numbness or tingling, and in severe cases, affect brainstem function.

The incidence of acoustic neuroma is estimated at 3–5 cases per 100,000 person-years, with higher prevalence among older adults, especially those over 70 years. While most cases occur sporadically, some are associated with neurofibromatosis type 2 (NF2), a genetic disorder that causes multiple tumors of the nervous system. Diagnosis is typically made through magnetic resonance imaging (MRI).

Current management strategies include active surveillance, microsurgical removal, and stereotactic radiosurgery, depending on tumor size, growth rate, symptoms, and patient health. There are currently no FDA-approved drugs for acoustic neuroma, though off-label treatments like bevacizumab show promise in selected cases, highlighting an unmet need for targeted medical therapies.

Do you know what will be the Acoustic Neuroma market share in 7MM by 2034 @ Acoustic Neuroma Treatment Market

Acoustic Neuroma Market Outlook

Between 2025 and 2034, the acoustic neuroma market is projected to grow steadily, fueled by improved diagnostics, increased awareness, and advances in treatments such as stereotactic radiosurgery, microsurgical techniques, and targeted therapies.

The aging population and higher prevalence of NF2-associated tumors are expanding the patient base. Novel drug candidates, notably Akouos’s AK-antiVEGF, aim to control tumor growth and preserve hearing, though no FDA-approved therapies currently exist for this condition. Present treatments—surgery, radiotherapy, and active surveillance—carry notable risks, highlighting the urgent need for safer, nerve-preserving options. Off-label use of agents like bevacizumab, lapatinib, and everolimus has shown promise, particularly in NF2 patients.

Acoustic neuroma typically causes hearing loss, tinnitus, dizziness, and facial numbness, with incidence increasing with age. Despite its benign nature, the tumor can cause debilitating symptoms. The current limited pipeline emphasizes a significant unmet need, but ongoing innovations suggest a potentially transformative decade ahead for acoustic neuroma management.

The acoustic neuroma market is driven by advancements in diagnostic imaging, increasing disease awareness, and improved treatment modalities such as stereotactic radiosurgery, microsurgical techniques, and targeted therapies. The rising prevalence of neurofibromatosis type 2 (NF2)-associated tumors, coupled with an aging global population, is expanding the patient pool. Additionally, the development of novel drug candidates like Akouos’s AK-antiVEGF, aimed at tumor control and hearing preservation, reflects growing research interest in addressing unmet needs.

However, market growth faces significant barriers, including the absence of FDA-approved drugs specifically for acoustic neuroma, a limited drug development pipeline, and the high risks associated with current treatment options such as surgery and radiotherapy. The rarity of the disease also limits large-scale clinical trials, slowing therapeutic innovation. Moreover, the benign nature of the tumor and the availability of active surveillance as a management strategy can reduce demand for aggressive interventions, creating further challenges in market expansion.

Acoustic Neuroma Epidemiology

The Acoustic Neuroma epidemiology section provides insights into the historical and current Acoustic Neuroma patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Acoustic Neuroma market report also provides the diagnosed patient pool, trends, and assumptions.

Segmented by:

Total incident Cases of acoustic neuroma
Total Diagnosed incident Cases of acoustic neuroma
Age-specific Cases of acoustic neuroma
Gender-specific Cases of acoustic neuroma

Some of the facts:

Acoustic neuromas are estimated to affect about 1 in 100,000 people in the general population.
Acoustic neuromas affect women more often than men. Most cases of acoustic neuroma develop in individuals between the ages of 30 and 60. Although quite rare, they can develop in children.

Interested to know how the emerging diagnostic approaches will be contributing in increased Acoustic Neuroma diagnosed prevalence pool? Download report @ Acoustic Neuroma Prevalence

Acoustic Neuroma Drugs Uptake

This section focuses on the uptake rate of the potential Acoustic Neuroma drugs recently launched in the Acoustic Neuroma market or expected to be launched in 2020-2034. The analysis covers the Acoustic Neuroma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Acoustic Neuroma Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Acoustic Neuroma market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acoustic Neuroma Pipeline Development Activities

The Acoustic Neuroma report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Acoustic Neuroma companies involved in developing targeted therapeutics.

Download report to know which TOP 3 therapies will be capturing the largest Acoustic Neuroma market share by 2034? Click here @ Acoustic Neuroma Medication and Drugs

Acoustic Neuroma Therapeutics Assessment

Major key companies are working proactively in the Acoustic Neuroma Therapeutics market to develop novel therapies which will drive the Acoustic Neuroma treatment markets in the upcoming years are Akouos, Amgen, Roche, Natus Medical Incorporated, Elekta, Pfizer Inc., Roche AG, CIVCO MEDICAL SOLUTIONS, Novartis AG, MAICO Diagnostics GmbH, Siemens Healthcare GmbH, Interacoustics A/S, Natus Medical Incorporated, and others.

Do you know how emerging drug launch will be impacting the Acoustic Neuroma market CAGR? Download sample report @ Acoustic Neuroma Clinical Trials and FDA Approvals

Acoustic Neuroma Report Key Insights

1. Acoustic Neuroma Patient Population

2. Acoustic Neuroma Market Size and Trends

3. Key Cross Competition in the Acoustic Neuroma Market

4. Acoustic Neuroma Market Dynamics (Key Drivers and Barriers)

5. Acoustic Neuroma Market Opportunities

6. Acoustic Neuroma Therapeutic Approaches

7. Acoustic Neuroma Pipeline Analysis

8. Acoustic Neuroma Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Acoustic Neuroma Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Acoustic Neuroma Competitive Intelligence Analysis

4. Acoustic Neuroma Market Overview at a Glance

5. Acoustic Neuroma Disease Background and Overview

6. Acoustic Neuroma Patient Journey

7. Acoustic Neuroma Epidemiology and Patient Population

8. Acoustic Neuroma Treatment Algorithm, Current Treatment, and Medical Practices

9. Acoustic Neuroma Unmet Needs

10. Key Endpoints of Acoustic Neuroma Treatment

11. Acoustic Neuroma Marketed Products

12. Acoustic Neuroma Emerging Therapies

13. Acoustic Neuroma Seven Major Market Analysis

14. Attribute Analysis

15. Acoustic Neuroma Market Outlook (7 major markets)

16. Acoustic Neuroma Access and Reimbursement Overview

17. KOL Views on the Acoustic Neuroma Market

18. Acoustic Neuroma Market Drivers

19. Acoustic Neuroma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acoustic Neuroma Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

Adenoid cystic carcinoma Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

“Adenoid cystic carcinoma Market”

Adenoid cystic carcinoma companies are OncoC4, Ascentage Pharma, Elevar Therapeutics, CELLESTIA BIOTECH AG, Remix Therapeutics, Rgenta Therapeutics Inc and others.

(Albany, USA) DelveInsight’s “Adenoid cystic carcinoma Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Adenoid cystic carcinoma, historical and forecasted epidemiology as well as the Adenoid cystic carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Adenoid cystic carcinoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Adenoid cystic carcinoma market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Adenoid cystic carcinoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Adenoid cystic carcinoma market.

Request for a Free Sample Report @ Adenoid cystic carcinoma Market Forecast

Some facts of the Adenoid cystic carcinoma Market Report are:

According to DelveInsight, Adenoid cystic carcinoma market size is expected to grow at a decent CAGR by 2034.
Leading Adenoid cystic carcinoma companies working in the market are OncoC4, Ascentage Pharma, Elevar Therapeutics, CELLESTIA BIOTECH AG, Remix Therapeutics, Rgenta Therapeutics Inc and others.
Key Adenoid cystic carcinoma Therapies expected to launch in the market are Gotistobart (ONC-392), Alrizomadlin (APG-115), REM-422, Emi-Le (XMT-1660), RGT-61159, and many others.
In June 2025, Ascentage Pharma announced new Phase II clinical data for its MDM2-p53 inhibitor, alrizomadlin (APG-115), at the 61st ASCO Annual Meeting. The study evaluated alrizomadlin alone or with PD-1 inhibitor toripalimab in patients with advanced adenoid cystic carcinoma and other solid tumors.
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced additional interim Phase 1 clinical data for emiltatug ledadotin (Emi-Le; XMT-1660), the company’s B7-H4-directed Dolasynthen ADC. These data are being presented in an oral session today at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago, Illinois. The presentation will focus on Emi-Le’s Phase 1 dose escalation and backfill cohorts as of a March 8, 2025 data cut-off in patients with triple-negative breast cancer (TNBC); hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; ovarian cancer; endometrial cancer and adenoid cystic carcinoma type 1 (ACC-1).
At the AACR Annual Meeting 2025, Remix Therapeutics presented new preclinical data in Session PO.ET09.10 highlighting REM-422, showing potent anti-tumor activity in xenograft models of adenoid cystic carcinoma underscoring its promise as a novel therapeutic strategy.
In October 2024, Rgenta Therapeutics announced the dosing of the first patients in a Phase I trial of RGT-61159, an oral small molecule targeting RNA regulation. The drug is being developed for adenoid cystic carcinoma, colorectal cancer, acute myeloid leukemia, and other solid tumors.

Adenoid cystic carcinoma Overview

Adenoid cystic carcinoma (ACC) is a rare, typically slow-growing malignancy that most often arises in the salivary glands but can also occur in other locations such as the lacrimal glands, trachea, breast, and skin. Despite its indolent growth, ACC is notorious for its tendency to invade surrounding nerves (perineural invasion) and its high risk of late local recurrence and distant metastases, particularly to the lungs, liver, and bones.

Clinically, Adenoid cystic carcinoma often presents as a painless mass in the affected gland or organ, with symptoms depending on the tumor’s location. For example, salivary gland ACC may cause facial numbness, weakness, or difficulty swallowing if cranial nerves are involved. The disease affects both men and women, typically in middle age, though it can occur at any age.

Adenoid cystic carcinoma Diagnosis is confirmed through histopathological examination, often supported by imaging techniques such as MRI or CT scans to assess local extension and metastasis. Surgical resection remains the primary treatment, frequently combined with postoperative radiotherapy to improve local control. Chemotherapy has limited effectiveness, but targeted and immunotherapeutic approaches are under investigation.

Due to its unpredictable behavior and risk of late metastasis, Adenoid cystic carcinoma requires long-term follow-up, making early detection and comprehensive management essential for improving patient outcomes.

Do you know what will be the Adenoid cystic carcinoma market share in 7MM by 2034 @ Adenoid Cystic Carcinoma Treatment Market

Adenoid cystic carcinoma Market

Adenoid cystic carcinoma (ACC) is the third most common malignant salivary gland tumor, predominantly affecting the submandibular gland but often originating from minor salivary glands in the palate, cheeks, sinuses, tongue, and other areas. The U.S. holds the largest ACC market compared to EU4, the UK, and Japan. With no approved systemic therapies, there is a critical unmet need driving innovation from companies like Elevar Therapeutics, Remix Therapeutics, Rgenta Therapeutics, and others. Promising pipeline candidates include alrizomadlin, Gotistobart, REM-422, and RGT-61159, with recent clinical and preclinical advancements presented at major oncology conferences, reflecting growing momentum toward novel targeted treatment strategies for ACC. During the forecast period, pipeline candidates such as Alrizomadlin, Gotistobart, REM-422, RGT-61159, and others are expected to drive the rise in Adenoid cystic carcinoma market size.

The adenoid cystic carcinoma (ACC) market is driven by several factors, primarily the rising incidence of malignant salivary gland tumors and the high unmet medical need due to the lack of approved systemic therapies. The disease’s aggressive nature, characterized by perineural invasion, local recurrence, and distant metastasis, fuels the demand for more effective treatment options. Advancements in molecular biology and precision medicine have accelerated the development of targeted therapies, including RNA-targeting drugs, antibody-drug conjugates (ADCs), and immunotherapies. Increasing investment by biotech companies such as Elevar Therapeutics, Rgenta Therapeutics, Remix Therapeutics, and Ascentage Pharma, combined with supportive regulatory incentives for rare cancers, is further driving research and innovation.

However, the market faces significant barriers. Adenoid cystic carcinoma’s rarity limits patient recruitment for large-scale clinical trials, slowing drug development timelines. The tumor’s slow-growing but persistent nature makes treatment response evaluation challenging, complicating clinical endpoints. Existing therapies, such as surgery and radiotherapy, offer limited efficacy in advanced disease, and chemotherapy remains largely ineffective. High R&D costs, coupled with uncertain commercial returns for orphan indications, may deter some industry players. Additionally, the biological complexity of Adenoid cystic carcinoma, including resistance mechanisms, poses a challenge in developing durable, broadly effective treatments. These factors collectively shape both the opportunities and obstacles in the Adenoid cystic carcinoma market.

According to DelveInsight, the Adenoid cystic carcinoma market in 7MM is expected to witness a major change in the study period 2020-2034.

Adenoid cystic carcinoma Epidemiology

The Adenoid cystic carcinoma epidemiology section provides insights into the historical and current Adenoid cystic carcinoma patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Adenoid cystic carcinoma market report also provides the diagnosed patient pool, trends, and assumptions.

Segmented by:

Incident Cases of Adenoid cystic carcinoma
Age-specific Cases of Adenoid cystic carcinoma
Gender-specific Cases of Adenoid cystic carcinoma
Site-specific Cases of Adenoid cystic carcinoma
Treated Cases of Adenoid cystic carcinoma

Interested to know how the emerging diagnostic approaches will be contributing in increased Adenoid cystic carcinoma patient pool? Download report @ Adenoid cystic carcinoma Incidence

Adenoid cystic carcinoma Drugs Uptake

This section focuses on the uptake rate of the potential Adenoid cystic carcinoma drugs recently launched in the Adenoid cystic carcinoma market or expected to be launched in 2020-2034. The analysis covers the Adenoid cystic carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Adenoid cystic carcinoma Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Adenoid cystic carcinoma market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Adenoid cystic carcinoma Pipeline Development Activities

The Adenoid cystic carcinoma report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Adenoid cystic carcinoma key players involved in developing targeted therapeutics.

Download report to know which TOP 3 therapies will be capturing the largest Adenoid cystic carcinoma market share by 2034? Click here @ Adenoid cystic carcinoma Clinical Trials and FDA Approvals

Adenoid cystic carcinoma Therapeutics Assessment

Major key companies are working proactively in the Adenoid cystic carcinoma Therapeutics market to develop novel therapies which will drive the Adenoid cystic carcinoma treatment markets in the upcoming years are OncoC4, Ascentage Pharma, Elevar Therapeutics, CELLESTIA BIOTECH AG, Remix Therapeutics, Rgenta Therapeutics Inc and others.

Do you know how emerging drug launch will be impacting the Adenoid cystic carcinoma market CAGR? Download sample report @ Adenoid cystic carcinoma Drugs Market

Adenoid cystic carcinoma Report Key Insights

1. Adenoid cystic carcinoma Patient Population

2. Adenoid cystic carcinoma Market Size and Trends

3. Key Cross Competition in the Adenoid cystic carcinoma Market

4. Adenoid cystic carcinoma Market Dynamics (Key Drivers and Barriers)

5. Adenoid cystic carcinoma Market Opportunities

6. Adenoid cystic carcinoma Therapeutic Approaches

7. Adenoid cystic carcinoma Pipeline Analysis

8. Adenoid cystic carcinoma Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Adenoid cystic carcinoma Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Adenoid cystic carcinoma Competitive Intelligence Analysis

4. Adenoid cystic carcinoma Market Overview at a Glance

5. Adenoid cystic carcinoma Disease Background and Overview

6. Adenoid cystic carcinoma Patient Journey

7. Adenoid cystic carcinoma Epidemiology and Patient Population

8. Adenoid cystic carcinoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Adenoid cystic carcinoma Unmet Needs

10. Key Endpoints of Adenoid cystic carcinoma Treatment

11. Adenoid cystic carcinoma Marketed Products

12. Adenoid cystic carcinoma Emerging Therapies

13. Adenoid cystic carcinoma Seven Major Market Analysis

14. Attribute Analysis

15. Adenoid cystic carcinoma Market Outlook (7 major markets)

16. Adenoid cystic carcinoma Access and Reimbursement Overview

17. KOL Views on the Adenoid cystic carcinoma Market

18. Adenoid cystic carcinoma Market Drivers

19. Adenoid cystic carcinoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Adenoid cystic carcinoma Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

Soft tissue sarcoma Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

“Soft tissue sarcoma Market”

Leading Soft tissue sarcoma companies working in the market are Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, more

(Albany, USA) DelveInsight’s “Soft tissue sarcoma Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Soft tissue sarcoma, historical and forecasted epidemiology as well as the Soft tissue sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

In 2025, ~13,520 new U.S. soft tissue sarcoma (STS) cases are expected, with common types including undifferentiated pleomorphic sarcoma, liposarcoma, and leiomyosarcoma. Diagnosis can be challenging due to subtype overlap. Current treatments for advanced STS historically rely on chemotherapy, but FDA approvals for targeted agents like AYVAKIT and TAZVERIK, alongside regorafenib and pazopanib, have expanded options. Emerging drugs such as Fibromun and INT230-6 are in late-stage trials, aiming to improve efficacy and reduce toxicity. Surgery remains critical for localized disease, with radiotherapy as adjunctive therapy. Immunotherapy, oncolytic viruses, and next-generation sequencing are shaping future strategies. The U.S. leads the STS market, followed by Germany in the EU4. Key players include Philogen, Intensity Therapeutics, Eli Lilly, and others. Uptake of new therapies will depend on competitive positioning, safety, efficacy, and regulatory approval. Expert insights highlight encouraging outcomes from novel combination therapies, indicating a promising evolution in STS management.

Request for a Free Sample Report @ Soft tissue sarcoma Market Forecast

Some facts of the Soft tissue sarcoma Market Report are:

According to DelveInsight, Soft tissue sarcoma market size is expected to grow at a decent CAGR by 2034.
In 2024, the United States accounted for the largest market size of Soft tissue sarcoma, in comparison to EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Leading Soft tissue sarcoma companies working in the market are Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
Key Soft tissue sarcoma Therapies expected to launch in the market are AL3818, L19 TNF, Camsirubicin, and others.
In July 2025, John Rieth announced a study is designed to treat locally advanced soft tissue sarcoma (STS) subtypes with neoadjuvant talimogene laherparepvec (TVEC) and preoperative external beam radiation therapy (EBRT).
In July 2025, Eli Lilly and Company conducted a study is to evaluate the efficacy of the combination of doxorubicin plus the study drug known as olaratumab versus doxorubicin plus placebo in participants with advanced or metastatic soft tissue sarcoma.
In July 2025, Polaris Group conducted a phase 3 trial that will compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
In 2025, approximately 13,520 new cases of soft tissue sarcoma are expected to be diagnosed in the United States, including about 7,600 in males and 5,920 in females, according to the American Cancer Society.
The most common soft tissue sarcomas in adults include undifferentiated pleomorphic sarcoma, liposarcoma, and leiomyosarcoma.

Soft tissue sarcoma Overview

Soft tissue sarcoma (STS) is a rare and heterogeneous group of malignant tumors that arise from the soft tissues of the body, including muscles, fat, blood vessels, nerves, tendons, and connective tissues. Accounting for less than 1% of all adult cancers, STS can develop in any part of the body but is most commonly found in the extremities, trunk, retroperitoneum, and head and neck region. There are more than 50 histological subtypes, such as liposarcoma, leiomyosarcoma, synovial sarcoma, and undifferentiated pleomorphic sarcoma, each with distinct biological behavior and treatment response.

The exact cause of Soft tissue sarcoma is often unknown, but risk factors include prior radiation therapy, certain genetic syndromes (e.g., Li-Fraumeni syndrome, neurofibromatosis type 1), chronic lymphedema, and exposure to specific chemicals. Soft tissue sarcoma Symptoms vary depending on the tumor’s size and location, with painless swelling or a growing mass being common early signs.

Soft tissue sarcoma Diagnosis typically involves imaging studies such as MRI or CT scans, followed by biopsy for histopathological confirmation. Standard treatment includes surgical resection with clear margins, often combined with radiotherapy and, in certain cases, chemotherapy or targeted therapy. Despite advances, recurrence and metastasis remain challenges, emphasizing the need for ongoing research into more effective systemic treatments for Soft tissue sarcoma.

Learn more about Soft tissue sarcoma treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Soft tissue sarcoma Treatment Market

Soft tissue sarcoma Market Outlook

According to DelveInsight, the Soft tissue sarcoma market in 7MM is expected to witness a major change in the study period 2020-2034.

The soft tissue sarcoma (STS) market is driven by increasing disease awareness, advances in diagnostic imaging, and the development of novel targeted therapies and immunotherapies. Growing research into the molecular biology of STS has led to precision medicine approaches, enabling subtype-specific treatments such as tyrosine kinase inhibitors (e.g., pazopanib) and monoclonal antibodies. Rising incidence rates, supportive regulatory frameworks for orphan diseases, and expanding clinical trial activity further boost market growth. The entry of innovative therapies and combination regimens is improving patient outcomes, creating opportunities for pharmaceutical companies to address unmet needs in advanced and metastatic disease.

However, market growth is hindered by several barriers, including the rarity and heterogeneity of STS, which complicates diagnosis, limits large-scale clinical trial enrollment, and delays drug development. Many subtypes respond poorly to conventional chemotherapy, and treatment resistance remains a major challenge. High costs of novel therapies, coupled with limited access in low- and middle-income regions, further restrict market expansion. Additionally, the lack of reliable biomarkers for early detection and treatment monitoring poses a significant hurdle. Overall, while scientific advances and investment are fueling progress, the complex nature of STS continues to challenge both clinical management and market growth.

Soft tissue sarcoma Epidemiology

The Soft tissue sarcoma epidemiology section provides insights into the historical and current Soft tissue sarcoma patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Soft tissue sarcoma market report also provides the diagnosed patient pool, trends, and assumptions.

Segmented by:

Total incident cases of soft tissue sarcoma
Gender-specific cases of soft tissue sarcomas
Type-specific cases of soft tissue sarcoma
Age-specific cases of soft tissue sarcoma
Stage-specific cases of soft tissue sarcoma
Extremities-specific cases of soft tissue sarcoma
Total Treated cases of soft tissue sarcoma

Explore more about Soft tissue sarcoma Epidemiology @ Soft tissue sarcoma Market Dynamics

Soft tissue sarcoma Drugs Uptake

This section focuses on the uptake rate of the potential Soft tissue sarcoma drugs recently launched in the Soft tissue sarcoma market or expected to be launched in 2025-2034. The analysis covers the Soft tissue sarcoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Soft tissue sarcoma Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Soft tissue sarcoma market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Soft tissue sarcoma Pipeline Development Activities

The Soft tissue sarcoma report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Soft tissue sarcoma key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Soft tissue sarcoma pipeline development activities @ Soft tissue sarcoma Medication and Companies

Soft tissue sarcoma Therapeutics Assessment

Major key companies are working proactively in the Soft tissue sarcoma market to develop novel therapies which will drive the Soft tissue sarcoma treatment markets in the upcoming years are Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.

Learn more about the emerging Soft tissue sarcoma therapies & key companies @ Soft tissue sarcoma Clinical Trials and FDA Approvals

Soft tissue sarcoma Report Key Insights

1. Soft tissue sarcoma Patient Population

2. Soft tissue sarcoma Market Size and Trends

3. Key Cross Competition in the Soft tissue sarcoma Market

4. Soft tissue sarcoma Market Dynamics (Key Drivers and Barriers)

5. Soft tissue sarcoma Market Opportunities

6. Soft tissue sarcoma Therapeutic Approaches

7. Soft tissue sarcoma Pipeline Analysis

8. Soft tissue sarcoma Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Soft tissue sarcoma Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Soft tissue sarcoma Competitive Intelligence Analysis

4. Soft tissue sarcoma Market Overview at a Glance

5. Soft tissue sarcoma Disease Background and Overview

6. Soft tissue sarcoma Patient Journey

7. Soft tissue sarcoma Epidemiology and Patient Population

8. Soft tissue sarcoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Soft tissue sarcoma Unmet Needs

10. Key Endpoints of Soft tissue sarcoma Treatment

11. Soft tissue sarcoma Marketed Products

12. Soft tissue sarcoma Emerging Therapies

13. Soft tissue sarcoma Seven Major Market Analysis

14. Attribute Analysis

15. Soft tissue sarcoma Market Outlook (7 major markets)

16. Soft tissue sarcoma Access and Reimbursement Overview

17. KOL Views on the Soft tissue sarcoma Market

18. Soft tissue sarcoma Market Drivers

19. Soft tissue sarcoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Soft tissue sarcoma Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

Acute Agitation and Aggression Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

“Acute Agitation and Aggression Market”

Acute Agitation and Aggression companies are BioXcel Therapeutics, Otsuka Pharmaceutical/Lundbeck, Axsome Therapeutics, Suven Life Sciences, Intra-Cellular Therapies/Johnson & Johnson, Others.

(Albany, USA) DelveInsight’s report, “Acute Agitation and Aggression Market Insights, Epidemiology, and Market Forecast–2034”, offers a comprehensive analysis of Acute Agitation and Aggression, including historical and projected epidemiology, along with market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The report examines current treatment practices, emerging therapies, market share by individual drugs, and the Acute Agitation and Aggression market size from 2020 to 2034, segmented across the seven major markets. It also outlines existing treatment algorithms, key market drivers and barriers, and prevailing unmet medical needs, aiming to identify the most promising opportunities. Furthermore, it evaluates the overall market potential, providing valuable insights for stakeholders to understand the evolving treatment landscape and growth prospects in Acute Agitation and Aggression management.

Request for a Free Sample Report @ Acute Agitation and Aggression Market Forecast

Some facts of the Acute Agitation and Aggression Market Report are:

According to DelveInsight, Acute Agitation and Aggression market size is expected to grow at a decent CAGR by 2034.
Leading Acute Agitation and Aggression companies working in the market are BioXcel Therapeutics, Otsuka Pharmaceutical/Lundbeck, Axsome Therapeutics, Suven Life Sciences, Intra-Cellular Therapies/Johnson & Johnson, Others.
Key Acute Agitation and Aggression Therapies expected to launch in the market are IGALMI (dexmedetomidine), REXULTI (brexpiprazole), AUVELITY (dextromethorphan-bupropion; AXS-05), Masupirdine (SUVN-502), ITI-1284, and many others.
In April 2025, Suven Life Sciences presented updated clinical data and outlined development plans for masupirdine’s Phase III program at the American Academy of Neurology (AAN) Annual Meeting.
In December 2024, Axsome announced the successful completion of its Phase III clinical program for AXS-05, which included the ADVANCE-1 Phase II/III trial, the ADVANCE-2, ACCORD-1, and ACCORD-2 Phase III trials, as well as an open-label extension study assessing long-term safety and efficacy.
According to the secondary search, acute agitation accounted for 4.6% of psychiatric emergencies in Europe.
Across Germany, Spain, and the UK, agitation was reported in 55% of patients with schizophrenia and 66% of those with bipolar disorder.
In Germany, Spain, and the UK, common symptoms reported during agitation episodes included feeling uneasy 64%, restless 63%, and nervous 63%, along with other symptoms such as feeling tense and being unable to sit still.

Acute Agitation and Aggression Overview

Acute agitation and aggression are behavioral states characterized by excessive motor activity, heightened arousal, and an increased potential for harmful actions toward oneself or others. They can occur suddenly and are often associated with psychiatric conditions such as schizophrenia, bipolar disorder, major depressive disorder, or dementia, as well as neurological disorders, substance intoxication or withdrawal, and certain medical conditions. Acute agitation typically manifests as restlessness, irritability, excessive talking, pacing, clenched fists, or heightened emotional tension, while aggression involves overt verbal or physical hostility.

These episodes may be triggered by underlying mental health conditions, environmental stressors, pain, fear, or unmet needs. If left unmanaged, they can escalate quickly, posing safety risks to patients, caregivers, and healthcare providers. Diagnosis involves assessing the severity, underlying cause, and potential risk factors through patient history, observation, and clinical evaluation.

Management focuses on rapid de-escalation to ensure safety. Non-pharmacological approaches include verbal de-escalation, environmental modification, and behavioral interventions. Pharmacological treatment may involve antipsychotics, benzodiazepines, or mood stabilizers, chosen based on the underlying cause and patient profile. Early recognition and timely intervention are crucial to prevent harm and improve outcomes, with ongoing care aimed at addressing the root cause and reducing recurrence.

Do you know what will be the Acute Agitation and Aggression market share in 7MM by 2034 @ Acute Agitation and Aggression Market Outlook

Acute Agitation and Aggression Market

The acute agitation and aggression market is expected to grow steadily from 2025–2034, driven by rising psychiatric disorder prevalence, aging populations, substance use, and cognitive decline. Current treatments include IGALMI, offering rapid sublingual relief for schizophrenia- and bipolar-related episodes, and REXULTI, approved for Alzheimer’s-related agitation, highlighting label expansion into neurodegenerative conditions. However, no single therapy yet provides both fast onset and sustained control across psychiatric, neurodegenerative, and pediatric cases with minimal side effects. Emerging candidates like AUVELITY, masupirdine, and ITI-1284 are in development, and their anticipated approvals are likely to intensify competition, accelerating market growth and expanding treatment options.

The acute agitation and aggression market is driven by the rising prevalence of psychiatric and neurodegenerative disorders, increasing substance use, aging populations, and advancements in rapid-acting therapeutic options. Growing R&D investments and novel drug approvals, such as IGALMI and REXULTI, are expanding treatment choices and addressing unmet needs. However, market growth is hindered by the absence of a single therapy offering both rapid and sustained symptom control across diverse patient groups, limited long-term safety data, and challenges in pediatric treatment. Additionally, regulatory hurdles, side-effect profiles, and the complexity of conducting large-scale trials in acute behavioral emergencies remain significant barriers.

According to DelveInsight, the Acute Agitation and Aggression market in 7MM is expected to witness a major change in the study period 2020-2034.

Acute Agitation and Aggression Epidemiology

The Acute Agitation and Aggression epidemiology section provides insights into the historical and current Acute Agitation and Aggression patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Acute Agitation and Aggression market report also provides the diagnosed patient pool, trends, and assumptions.

Segmented by:

Total Prevalent Cases Of Acute Agitation and Aggression
Total Diagnosed Prevalent Cases Of Acute Agitation and Aggression
Comorbidities-associated Cases of Acute Agitation and Aggression
Symptom-specific Cases of Acute Agitation and Aggression
Treated Cases of Acute Agitation and Aggression

Some of the facts:

According to the secondary search, acute agitation accounted for 4.6% of psychiatric emergencies in Europe.
Across Germany, Spain, and the UK, agitation was reported in 55% of patients with schizophrenia and 66% of those with bipolar disorder.
In Germany, Spain, and the UK, common symptoms reported during agitation episodes included feeling uneasy 64%, restless 63%, and nervous 63%, along with other symptoms such as feeling tense and being unable to sit still.

Interested to know how the emerging diagnostic approaches will be contributing in increased Acute Agitation and Aggression diagnosed prevalence pool? Download report @ Acute Agitation and Aggression Treatment Market

Acute Agitation and Aggression Drugs Uptake

This section focuses on the uptake rate of the potential Acute Agitation and Aggression drugs recently launched in the Acute Agitation and Aggression market or expected to be launched in 2020-2034. The analysis covers the Acute Agitation and Aggression market uptake by drugs, patient uptake by therapies, and sales of each drug.

Acute Agitation and Aggression Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Acute Agitation and Aggression market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acute Agitation and Aggression Pipeline Development Activities

The Acute Agitation and Aggression report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Acute Agitation and Aggression key players involved in developing targeted therapeutics.

Download report to know which TOP 3 therapies will be capturing the largest Acute Agitation and Aggression market share by 2034? Click here @ Acute Agitation and Aggression Drugs and Therapies

Acute Agitation and Aggression Therapeutics Assessment

Major key companies are working proactively in the Acute Agitation and Aggression Therapeutics market to develop novel therapies which will drive the Acute Agitation and Aggression treatment markets in the upcoming years are BioXcel Therapeutics, Otsuka Pharmaceutical/Lundbeck, Axsome Therapeutics, Suven Life Sciences, Intra-Cellular Therapies/Johnson & Johnson, Others.

Do you know how new drug market launch will be impacting the Acute Agitation and Aggression market CAGR? Download sample report @ Acute Agitation and Aggression Clinical Trials and FDA Approvals

Acute Agitation and Aggression Report Key Insights

1. Acute Agitation and Aggression Patient Population

2. Acute Agitation and Aggression Market Size and Trends

3. Key Cross Competition in the Acute Agitation and Aggression Market

4. Acute Agitation and Aggression Market Dynamics (Key Drivers and Barriers)

5. Acute Agitation and Aggression Market Opportunities

6. Acute Agitation and Aggression Therapeutic Approaches

7. Acute Agitation and Aggression Pipeline Analysis

8. Acute Agitation and Aggression Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Acute Agitation and Aggression Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Acute Agitation and Aggression Competitive Intelligence Analysis

4. Acute Agitation and Aggression Market Overview at a Glance

5. Acute Agitation and Aggression Disease Background and Overview

6. Acute Agitation and Aggression Patient Journey

7. Acute Agitation and Aggression Epidemiology and Patient Population

8. Acute Agitation and Aggression Treatment Algorithm, Current Treatment, and Medical Practices

9. Acute Agitation and Aggression Unmet Needs

10. Key Endpoints of Acute Agitation and Aggression Treatment

11. Acute Agitation and Aggression Marketed Products

12. Acute Agitation and Aggression Emerging Therapies

13. Acute Agitation and Aggression Seven Major Market Analysis

14. Attribute Analysis

15. Acute Agitation and Aggression Market Outlook (7 major markets)

16. Acute Agitation and Aggression Access and Reimbursement Overview

17. KOL Views on the Acute Agitation and Aggression Market

18. Acute Agitation and Aggression Market Drivers

19. Acute Agitation and Aggression Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Agitation and Aggression Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight